| Product Code: ETC8284216 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Mexico Neurodegenerative Disease Treatment Market Overview |
3.1 Mexico Country Macro Economic Indicators |
3.2 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Mexico Neurodegenerative Disease Treatment Market - Industry Life Cycle |
3.4 Mexico Neurodegenerative Disease Treatment Market - Porter's Five Forces |
3.5 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Drug Type:, 2021 & 2031F |
3.7 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Route of Administration:, 2021 & 2031F |
3.8 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Distribution Channel:, 2021 & 2031F |
4 Mexico Neurodegenerative Disease Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of neurodegenerative diseases in Mexico |
4.2.2 Technological advancements in treatment options |
4.2.3 Rising healthcare expenditure and investments in neurology research |
4.3 Market Restraints |
4.3.1 Limited access to specialized neurology care in certain regions of Mexico |
4.3.2 High cost of neurodegenerative disease treatments |
4.3.3 Stringent regulations and approval processes for new treatments |
5 Mexico Neurodegenerative Disease Treatment Market Trends |
6 Mexico Neurodegenerative Disease Treatment Market, By Types |
6.1 Mexico Neurodegenerative Disease Treatment Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Indication, 2021- 2031F |
6.1.3 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Multiple Sclerosis, 2021- 2031F |
6.1.4 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Parkinsons Disease, 2021- 2031F |
6.1.5 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Alzheimers Disease, 2021- 2031F |
6.1.6 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Spinal Muscular Atrophy (SMA), 2021- 2031F |
6.1.7 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Huntingtons Disease, 2021- 2031F |
6.1.8 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Mexico Neurodegenerative Disease Treatment Market, By Drug Type: |
6.2.1 Overview and Analysis |
6.2.2 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By N-methyl-D-aspartate Receptor Antagonists, 2021- 2031F |
6.2.3 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Selective Serotonin Reuptake Inhibitors, 2021- 2031F |
6.2.4 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Dopamine Inhibitors, 2021- 2031F |
6.2.5 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Mexico Neurodegenerative Disease Treatment Market, By Route of Administration: |
6.3.1 Overview and Analysis |
6.3.2 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Injectable, 2021- 2031F |
6.3.4 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Mexico Neurodegenerative Disease Treatment Market, By Distribution Channel: |
6.4.1 Overview and Analysis |
6.4.2 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.4.3 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.4.4 Mexico Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
7 Mexico Neurodegenerative Disease Treatment Market Import-Export Trade Statistics |
7.1 Mexico Neurodegenerative Disease Treatment Market Export to Major Countries |
7.2 Mexico Neurodegenerative Disease Treatment Market Imports from Major Countries |
8 Mexico Neurodegenerative Disease Treatment Market Key Performance Indicators |
8.1 Patient enrollment in clinical trials for neurodegenerative disease treatments |
8.2 Adoption rate of innovative treatments in neurology clinics |
8.3 Number of neurologists specializing in neurodegenerative diseases in Mexico |
9 Mexico Neurodegenerative Disease Treatment Market - Opportunity Assessment |
9.1 Mexico Neurodegenerative Disease Treatment Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 Mexico Neurodegenerative Disease Treatment Market Opportunity Assessment, By Drug Type:, 2021 & 2031F |
9.3 Mexico Neurodegenerative Disease Treatment Market Opportunity Assessment, By Route of Administration:, 2021 & 2031F |
9.4 Mexico Neurodegenerative Disease Treatment Market Opportunity Assessment, By Distribution Channel:, 2021 & 2031F |
10 Mexico Neurodegenerative Disease Treatment Market - Competitive Landscape |
10.1 Mexico Neurodegenerative Disease Treatment Market Revenue Share, By Companies, 2024 |
10.2 Mexico Neurodegenerative Disease Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here